Cant comment on the quality of the article, study or journal, (but its not the new idea......) however, as you sugegsted it highlights the additional conventiopnal costs that are reduced or elimianted with TAVR.
While the TAVR hardware is many times more expensive ($30 k v $5k)...... the reduced costs and eliminations of OT, CP Bypass, reduced ICU recovery time, and overal length of stay, this article suggets that the procedure and hospital cost is slightly greater for TAVR (<$3000, or 5%) however, in the following two years, the conventional alternative is >$9000 or 9% more expensive than the TAVR approach.
link below.
- Forums
- ASX - By Stock
- AHZ
- News: AHZ Admedus Says Cardiocel 3D And Vascucel Receives European Regulatory Approval
News: AHZ Admedus Says Cardiocel 3D And Vascucel Receives European Regulatory Approval, page-442
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AHZ (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online